Tramiprosate

被引:35
作者
Wright, Tamsin M. [1 ]
机构
[1] Prous Sci, Dept Med Informat, E-08025 Barcelona, Spain
关键词
D O I
10.1358/dot.2006.42.5.973584
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Current treatment options for patients with Alzheimer's disease are limited to providing symptomatic relief, with no effects on the underlying pathophysiology. However, a greater understanding of the importance of beta-amyloid peptides (Abeta) in the pathogenesis of this disease has led to the investigation of a number of potential antiamyloid therapies, of which tramiprosate (Neurochem Inc.) is in the most advanced stage of development. Tramiprosate is a glycosaminoglycan (GAG) mimetic designed to interfere with the actions of Abeta early in the cascade of amyloidogenic events. Preclinical data have shown that tramiprosate reduces brain and plasma levels of Abeta, prevents fibril formation and exerts cytoprotective effects in the brain. The pharmacological effects have also been demonstrated in clinical trials of patients with mild to moderate Alzheimer's disease. Promising findings for the efficacy of tramiprosate, indicated by improvement or stabilization of cognitive function, have been shown in phase 11 clinical trials and open-label extensions of these studies. Furthermore, tramiprosate appears to be well tolerated with no reports of safety concerns. This article reviews the unique mode of action of tramiprosate and summarizes the available clinical information on the effects of tramiprosate in patients with Alzheimer's disease. (c) 2006 Prous Science. All rights reserved.
引用
收藏
页码:291 / 298
页数:8
相关论文
共 55 条
[1]   An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting [J].
Aguglia, E ;
Onor, ML ;
Saina, M ;
Maso, E .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (11) :1747-1752
[2]  
AISEN P, 2005, 7 ALZH PARK DIS INT
[3]   Clinical data on Alzhemed™ after 12 months of treatment in patients with mild to moderate Alzheimer's disease [J].
Aisen, PA ;
Mehran, M ;
Poole, R ;
Lavoie, I ;
Gervais, F ;
Laurin, J ;
Briand, R ;
Garceau, D .
NEUROBIOLOGY OF AGING, 2004, 25 :S20-S20
[4]   The development of anti-amyloid therapy for Alzheimer's disease - From secretase modulators to polymerisation inhibitors [J].
Aisen, PS .
CNS DRUGS, 2005, 19 (12) :989-996
[5]  
BILIKIEWICZ A, 2002, MED SCI MONITOR, V8, pPL9
[6]  
Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub2, 10.1002/14651858.CD001190.pub3]
[7]   CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects [J].
Buerger, K ;
Teipel, SJ ;
Zinkowski, R ;
Blennow, K ;
Arai, H ;
Engel, R ;
Hofmann-Kiefer, K ;
McCulloch, C ;
Ptok, U ;
Heun, R ;
Andreasen, N ;
DeBernardis, J ;
Kerkman, D ;
Moeller, HJ ;
Davies, P ;
Hampel, H .
NEUROLOGY, 2002, 59 (04) :627-629
[8]   The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation [J].
Castillo, GM ;
Lukito, W ;
Wight, TN ;
Snow, AD .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (04) :1681-1687
[9]   Cerebrospinal fluid tau and β-amyloid -: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? [J].
Clark, CM ;
Xie, S ;
Chittams, J ;
Ewbank, D ;
Peskind, E ;
Galasko, D ;
Morris, JC ;
McKeel, DW ;
Farlow, M ;
Weitlauf, SL ;
Quinn, J ;
Kaye, J ;
Knopman, D ;
Arai, H ;
Doody, RS ;
DeCarli, C ;
Leight, S ;
Lee, VMY ;
Trojanowski, JQ .
ARCHIVES OF NEUROLOGY, 2003, 60 (12) :1696-1702
[10]   Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment [J].
de Leon, MJ ;
Segal, S ;
Tarshish, CY ;
DeSanti, S ;
Zinkowski, R ;
Mehta, PD ;
Convit, A ;
Caraos, C ;
Rusinek, H ;
Tsui, W ;
Saint Louis, LA ;
DeBernardis, J ;
Kerkman, D ;
Qadri, F ;
Gary, A ;
Lesbre, P ;
Wisniewski, T ;
Poirier, J ;
Davies, P .
NEUROSCIENCE LETTERS, 2002, 333 (03) :183-186